Overview
AZN market data
Price History
AZN price chart · 1M
- O
- 162.85
- H
- 163.70
- L
- 161.14
- C
- 162.67
- Vol
- 113,161.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $162.85
- Previous Close
- $164.71
- Day High
- $163.70
- Day Low
- $161.14
- 52 Week High
- $195.12
- 52 Week Low
- $152.45
- 7 Day Return
- -0.01%
- 30 Day Return
- +1.42%
- 90 Day Return
- -9.86%
- 1 Year Return
- -9.96%
- Daily Notional Volume
- $18.4M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 18.03 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $6.55 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.39 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 2.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 17.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $10,784.00 – $15,730.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $188.4B · P/B 4.38 · P/S 3.07.
Company News
10 captured
AZN Stock Down 20% in 6 Months: How to Play After Pipeline SetbacksZacks Investment Research ·
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets GoalZacks Investment Research ·
Breast Cancer Therapeutics Market Size to Reach USD 95.14 Billion at a CAGR of 9.20% from 2035 – SNS InsiderGlobenewswire Inc ·
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer StudyZacks Investment Research ·